Exploring Residual Concentrations of Agents in Head and Neck Cancer

Joseph Ciccolini, PhD
Published: Monday, Apr 10, 2017



Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Aside from cetuximab (Erbitux), researchers are working on this novel method with bevacizumab (Avastin). However, the clinical outcomes with this agent are not yet available.

Furthermore, he adds, agents including nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) are being investigated for residual concentrations. This is because these drugs are effective, but they could be improved and show activity in more patients with different doses or scheduling, Ciccolini explains.
SELECTED
LANGUAGE


Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Aside from cetuximab (Erbitux), researchers are working on this novel method with bevacizumab (Avastin). However, the clinical outcomes with this agent are not yet available.

Furthermore, he adds, agents including nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) are being investigated for residual concentrations. This is because these drugs are effective, but they could be improved and show activity in more patients with different doses or scheduling, Ciccolini explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x